About: Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $21.45 (+1.37%)
CUE NASDAQ Cue Biopharma
Cue Biopharma share price
Atividade de preço de CUE
Último preço
$ 21,450
Variação (24h)
0,29 USD (1,37%)
Volume
94.66K
Volume (média 4 sem.)
-
Abertura
$ 20,97
Variação do dia
$ 20,74 - $ 22,49
Fechamento anterior
$ 21,16
Último negócio
29 Oct, 8:26 pm GMT+0
Atrasado
29 Oct, 8:26 pm GMT+0
CUE price performance
Atrasado
29 Oct, 8:26 pm GMT+0
quote.marketSignals